

Case of generalized morphea complicated with systemic sclerosis

Soichiro Sawamura, Katsunari Makino, Hitomi Nakashima, Takamitsu Makino, Satoshi Fukushima

Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

Key words: localized scleroderma; antinuclear antibody; anti-centromere antibody; hyperpigmentation.

Correspondence: Katsunari Makino, Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556 Japan. Tel.: +81-96-373-5233. Fax: +81-96-373-5235. E-mail: katsuderma@gmail.com

Dear Editor,

Localized scleroderma (LSc; morphea) is a rare fibrosing disease of the skin and underlying tissues, which is different from systemic sclerosis (SSc).¹ LSc is classified based on clinical presentations: circumscribed, linear, generalized, pansclerotic, and mixed morphea.¹ Generalized morphea (GM), which is characterized by wide-

spread skin lesions with multiple indurated plaques or hyperpigmentation, is a relatively rare subtype occurring in 7-9% of patients with LSc.¹ Previous studies have shown that SSc can be complicated by GM, separately from GM-like SSc. Here, we present a rare case of coexistence of LSc and SSc in which LSc skin lesions appeared before SSc became apparent.

A 49-year-old woman visited our hospital for finger stiffness and




Figure 1. A) Skin thickening of both hands. B) Nailfold bleeding on the left forefinger as seen on dermoscopy. C) Morphea lesions on both legs. D) Irregular indurated plaques with erythematous border (lilac ring) on the right thigh.

Raynaud's phenomenon for a year or two, in conjunction with hyperpigmentation on the lower limbs for approximately 5 years. She had a history of chronic thyroiditis. She had been employed as an office worker for about 30 years. Physical examination revealed skin thickening on both hands (Figure 1A), nailfold bleeding on the left forefinger (Figure 1B), and hyperpigmentation of the limbs. The modified Rodnan total skin thickness score was 4. Laboratory examinations revealed almost normal results, except for an elevated serum antinuclear antibody titer of $\times 1280$ (reference range: $<40\times$) and positive anti-centromere antibodies. Gastroesophageal reflux disease was found on endoscopic examination. Computed tomography did not confirm interstitial lung disease. Thus, she was diagnosed with limited cutaneous SSc (lcSSc) according to the 2013 Classification Criteria for systemic sclerosis (ACR/EULAR) and the classification proposed by LeRoy *et al.*² At follow-up, an oral proton pump inhibitor for gastroesophageal reflux disease, and within 1-year, peripheral erythema (called "lilac ring") with itching around the hyperpigmentation on the thighs developed (Figure 1 C,D). Additionally, the hyperpigmented lesions gradually enlarged and became indurated. Histological findings from the left thigh biopsy showed a thickened dermis with swollen collagen bundles and mild perivascular lymphocytic infiltrates. We considered that morphea lesions occurred before the onset of lcSSc and recurred during follow-up. Considering all these, we diagnosed her with GM complicated with lcSSc and treated her with systemic corticosteroid (oral prednisolone, 30 mg/day). The possibility of GM-like SSc was excluded due to the clinical course and occupational history. The coexistence of LSc and SSc had been previously described in

4.9-6.7% of patients with SSc.³ The presence of anti-centromere antibodies in SSc patients complicated by LSc is less frequent than in SSc patients without LSc.⁴ To the best of our knowledge, this is the first case of GM complicated with anti-centromere antibody-positive lcSSc.⁴ Mizutani *et al.* reported a case of SSc with repeated recurrent morphea as *palindromic morphea*.⁵ Hayashi *et al.* also reported recurrence of morphea lesions in a patient with SSc complicated by GM when the dose of corticosteroid was tapered.⁴ Therefore, our patient could have a high risk of recurrence and should undergo a more careful continuous management.

References

1. Laxer RM, Zulian F. Localized scleroderma. *Curr Opin Rheumatol* 2006;18:606-13.
2. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. *J Rheumatol* 2001;28:1573-6.
3. Toki S, Motegi S, Yamada K, et al. Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma. *J Dermatol* 2015;42:283-7.
4. Hayashi M, Ichiki Y, Kitajima Y. Coexistence of recurrent generalized morphea and systemic sclerosis. *Acta Derm Venereol* 2009;89:329-30.
5. Mizutani H, Tanaka H, Okada H, et al. Palindromic morphea: multiple recurrence of morphea lesions in a case of systemic sclerosis. *J Dermatol* 1992;19:298-301.

Received: 15 September 2021; Accepted: 16 September 2021.

Contributions: Soichiro Sawamura: data collection, writing – original draft; Katsunari Makino: revision; Hitomi Nakashima: data collection; Takamitsu Makino, Satoshi Fukushima: diagnosis and revision. All the authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conflict of interest: The authors declare no potential conflict of interest.

Ethics approval and consent to participate: no ethical committee approval was required because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).